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P EGINT E RF E RON AL FA- 2 a IN PATIENTS WITH C H R ONIC H EPATITIS C A ND CIRR H OSIS

PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C
AND CIRRHOSIS
E. JENNY HEATHCOTE, M.D., MITCHELL L. SHIFFMAN, M.D., W. GRAHAM E. COOKSLEY, M.D.,
GEOFFREY M. DUSHEIKO, M.D., SAMUEL S. LEE, M.D., LUIS BALART, M.D., ROBERT REINDOLLAR, M.D.,
RAJENDER K. REDDY, M.D., TERESA L. WRIGHT, M.D., AMY LIN, M.S., JOSEPH HOFFMAN, M.D.,
AND JEAN DE PAMPHILIS, PH.D.*

ABSTRACT
Background Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat.
In patients with chronic hepatitis C but without cirrhosis, once-weekly administration of interferon modified by the attachment of a 40-kd branched-chain
polyethylene glycol moiety (peginterferon alfa-2a) is
more efficacious than a regimen of unmodified interferon. We examined the efficacy and safety of peginterferon alfa-2a in patients with HCV-related cirrhosis or bridging fibrosis.
Methods We randomly assigned 271 patients with
cirrhosis or bridging fibrosis to receive subcutaneous treatment with 3 million units of interferon alfa-2a
three times weekly (88 patients), 90 µg of peginterferon alfa-2a once weekly (96), or 180 µg of peginterferon alfa-2a once weekly (87). Treatment lasted 48
weeks and was followed by a 24-week follow-up period. We assessed efficacy by measuring HCV RNA
and alanine aminotransferase and by evaluating liverbiopsy specimens. A histologic response was defined
as a decrease of at least 2 points on the 22-point Histological Activity Index.
Results In an intention-to-treat analysis, HCV RNA
was undetectable at week 72 in 8 percent, 15 percent,
and 30 percent of the patients treated with interferon
alfa-2a and with 90 µg and 180 µg of peginterferon
alfa-2a, respectively (P=0.001 for the comparison between 180 µg of peginterferon alfa-2a and interferon
alfa-2a). At week 72, alanine aminotransferase concentrations had normalized in 15 percent, 20 percent,
and 34 percent of patients, respectively (P=0.004 for
the comparison between 180 µg of peginterferon
alfa-2a and interferon alfa-2a). In the subgroup of 184
patients with paired liver-biopsy specimens, the rates
of histologic response at week 72 were 31 percent,
44 percent, and 54 percent, respectively (P=0.02 for
the comparison between 180 µg of peginterferon
alfa-2a and interferon alfa-2a). All three treatments
were similarly tolerated.
Conclusions In patients with chronic hepatitis C
and cirrhosis or bridging fibrosis, 180 µg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard
interferon alfa-2a administered three times weekly.
(N Engl J Med 2000;343:1673-80.)
©2000, Massachusetts Medical Society.

I

NTERFERON has had a fundamental role in
the treatment of patients with chronic hepatitis
C virus (HCV) infection. In patients with cirrhosis, interferon, either alone or in combination with ribavirin, has been used cautiously, largely
because it may exacerbate the patients’ neutropenia
and thrombocytopenia.1 In large trials of interferonbased therapies, the proportion of patients with HCVrelated advanced liver disease has been small,2-6 and
we are aware of only two studies that have focused
exclusively on such treatment in patients with HCVrelated cirrhosis.7,8
To overcome some of the drawbacks of interferon,
a modified form of the drug, called peginterferon
alfa-2a, was developed by attaching a 40-kd branchedchain polyethylene glycol moiety to interferon alfa2a.9-11 Recent data12 suggest that the sustained virologic response achieved with peginterferon alfa-2a is
similar to that observed for interferon alfa-2a in
combination with ribavirin in patients with hepatitis
C.13 In addition, the tolerability of peginterferon is
similar to that of the unmodified drug.12 We compared the efficacy and safety of two doses of peginterferon alfa-2a, each given once weekly, with the
efficacy and safety of a standard regimen of unmodified interferon alfa-2a in patients with hepatitis C
and cirrhosis or bridging fibrosis.
METHODS
Patients
Patients who had chronic HCV infection and biopsy-proved
liver cirrhosis or bridging fibrosis and who had not previously
been treated with interferon were eligible for the study if the following two conditions were met: the serum alanine aminotrans-
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ferase concentration had been abnormal on two occasions during
the preceding six months, and a liver biopsy had been performed
during the preceding year. Criteria for exclusion were the presence
of other liver diseases, decompensated cirrhosis, human immunodeficiency virus infection, psychiatric conditions, seizure disorders,
severe cardiac disease, retinopathy, cancer, a neutrophil count below 1500 per cubic millimeter, a platelet count below 75,000 per
cubic millimeter, and an alpha-fetoprotein concentration above
100 ng per milliliter.
Study Design
This open-label, randomized, parallel-dose study was conducted by the Pegasys International Study Group at 30 centers in the
United States, Canada, Australia, and the United Kingdom between
September 1997 and October 1999. The study was approved by
the ethics committees at each center, and all the patients provided
written informed consent. The trial was designed by F. Hoffmann–
LaRoche and by expert hepatologists in conjunction with the health
authorities in each country. F. Hoffmann–LaRoche was responsible for monitoring adherence to the International Conference on
Harmonization guidelines14 and for monitoring the analysis of
data collected by the investigators.
Patients who met the criteria for entry were randomly assigned
to receive, in a 1:1:1 ratio, interferon alfa-2a (Roferon-A, F. Hoffmann–LaRoche, Basel, Switzerland) at a dose of 3 million units
given subcutaneously three times weekly or peginterferon alfa-2a
(Pegasys, F. Hoffmann–LaRoche) at a dose of 90 µg or 180 µg
given subcutaneously once weekly. Randomization was performed
according to center, in blocks of six patients, and random assignments were made according to a computer-generated scheme managed by Applied Logistic Associates (Houston). Patients administered the study drug subcutaneously on an outpatient basis for 48
weeks and then were followed for the next 24 weeks.
Laboratory tests, including assessments of plasma HCV RNA
levels and serum alanine aminotransferase concentrations, viral
genotyping, and histologic evaluation of biopsy specimens, were
performed at central laboratories. Pretreatment biopsy specimens
were examined without blinding before randomization and were
subsequently coded and evaluated in parallel with those obtained
at week 72 by pathologists who were unaware of the patients’
treatment assignments. HCV genotyping was performed by sequence analysis of a portion of the 5' untranslated region of the
viral genome at the end of the study.15 Safety was assessed by analyzing the occurrence of adverse events, changes in vital signs, and
the results of laboratory tests recorded at weeks 1, 2, 4, 6, and 8
of the study and then every 4 weeks for the remainder of the 72week study period.
The protocol guidelines allowed dose modification (a 25, 50, or
75 percent reduction in the assigned dose) for patients who had
important adverse events or important abnormalities in laboratory
values. If a patient received more than three consecutive reduced
doses or more than a total of six reduced doses, the dose could
not subsequently be increased. Patients were withdrawn from the
study if they missed four consecutive weeks of treatment or if an
investigator was concerned about their safety.
Assessment of Efficacy
The primary end points were sustained virologic and biochemical responses. A sustained virologic response was defined as undetectable levels of HCV RNA (<100 copies per milliliter) on
analysis (Cobas Amplicor HCV Test [version 2.0], Roche Diagnostics, Branchburg, N.J.) at the end of the follow-up period. A
sustained biochemical response was defined as an alanine aminotransferase value below the upper limit of the normal range at the
end of the follow-up period. Other end points included virologic
and biochemical responses at the end of the 48-week treatment
period. Liver-biopsy specimens were evaluated for changes from
values at the beginning of treatment (base line) in the score on the
22-point Histological Activity Index, where inflammation is graded
from 0 (none) to 18 (severe) and fibrosis is graded from 0 (none)
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to 4 (cirrhosis).16 A histologic response at week 72 was defined as
a decrease of at least 2 points in the total score on this index (fibrosis
and inflammation scores combined, with a fibrosis score of 3 indicating bridging fibrosis).
Statistical Analysis
In comparisons of the peginterferon groups with the interferon
group, all categorical variables were analyzed with use of the Cochran–Mantel–Haenszel test, with stratification according to center.
To control the overall probability of a type I error (5 percent),
a two-sided significance level of 0.025 was used for the two pairwise treatment comparisons (peginterferon alfa-2a at each of two
doses vs. interferon alfa-2a). All end points (except for changes
from base-line histologic findings) were evaluated by intentionto-treat analysis. The analysis of histologic response included only
patients who underwent both a pretreatment biopsy and a biopsy
at week 72. The analysis of safety included all the patients who
received at least one dose of study medication and who underwent at least one assessment of safety during the study.

RESULTS
Characteristics of the Patients

Of the 397 patients screened, 271 met the criteria
for entry and underwent randomization. The main
reasons for exclusion from the study were histologic
features that did not suggest cirrhosis or bridging fibrosis (67 patients), a low platelet count (12), and a
normal alanine aminotransferase concentration (10);
37 patients were excluded for other reasons. Two patients assigned to interferon alfa-2a did not receive
treatment, and one assigned to 180 µg of peginterferon alfa-2a elected alternative therapy; all three
were included in the intention-to-treat analysis of efficacy. Characteristics of the patients at base line are
summarized in Table 1. All base-line characteristics,
including factors associated with treatment outcome,
were similar among the three groups.
Of the 271 eligible patients, 88 were randomly assigned to treatment with 3 million units of interferon alfa-2a, and 96 and 87 were randomly assigned
to treatment with 90 µg and 180 µg of peginterferon alfa-2a, respectively. Treatment was completed by
64, 78, and 67 patients, respectively, and follow-up
was completed by 68, 79, and 74 patients. Patients
who discontinued drug therapy were encouraged to
remain in the study for assessments through week
72. The main reasons for withdrawal were adverse
events, failure to return or refusal of treatment, insufficient therapeutic effects, or laboratory abnormalities (Table 2).
Virologic Response

The rates of sustained virologic response (the response at week 72) were 8 percent, 15 percent, and
30 percent in patients assigned to unmodified interferon alfa-2a, 90 µg of peginterferon alfa-2a, and 180
µg of peginterferon alfa-2a, respectively (P=0.001
for the comparison between 180 µg of peginterferon alfa-2a and interferon alfa-2a [Table 3]). A response
to therapy at week 12 predicted a sustained response;
at week 12, all of the 26 patients who had a sustained
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TABLE 1. CHARACTERISTICS

OF THE

CHARACTERISTIC

Male sex — no. (%)
Age — yr
Weight — kg
Body-mass index†
Race — no. (%)
White
Black
Asian
Other
Serum alanine aminotransferase (U/liter)‡
No. of HCV RNA copies/ml — ¬10¡6
Histological Activity Index score§
Mode of infection — no. (%)
Intravenous drug use
Transfusion
Other¶
Unspecified
Histologic diagnosis — no. (%)¿
Cirrhosis
Bridging fibrosis
HCV genotype
1
1a
1b
Other than 1
2
3
4
Other or unknown

PATIENTS

INTERFERON
ALFA-2a
(N=88)

AT

BASE LINE.*

PEGINTERFERON ALFA-2a
90 µg
(N=96)

180 µg
(N=87)

62 (70)
46.9±7.6
84.6±16.2
28.7±5.9

71 (74)
47.2±8.4
86.4±18.9
28.7±5.5

63 (72)
47.1±8.7
82.4±17.0
27.4±5.0

77 (88)
5 (6)
3 (3)
3 (3)
104.1±72.5
6.3±8.4
12.8±1.7

87 (91)
1 (1)
2 (2)
6 (6)
104.1±58.0
6.3±8.0
12.7±2.1

75 (86)
5 (6)
2 (2)
5 (6)
123.3±68.9
5.7±8.0
13.4±1.7

41
14
10
23

(47)
(16)
(11)
(26)

47
25
8
16

(49)
(26)
(8)
(17)

42
28
9
8

(48)
(32)
(10)
(9)

67 (76)
21 (24)

76 (79)
19 (20)

69 (79)
18 (21)

47
28
19
41
12
27
0
2

58
27
31
38
7
26
2
3

48
33
15
39
14
20
1
4

(53)
(32)
(22)
(47)
(14)
(31)
(2)

(60)
(28)
(32)
(40)
(7)
(27)
(2)
(3)

(55)
(38)
(17)
(45)
(16)
(23)
(1)
(5)

*Plus–minus values are means ±SD. Because of rounding, not all percentages total 100.
†Body-mass index was calculated as the weight in kilograms divided by the square of the height in
meters.
‡For each patient, the average of the two pretreatment values meeting the entry criteria was calculated.
§The score is based on the evaluation of the pretreatment biopsy specimen.
¶Other modes of infection included use of drugs other than intravenous drugs, occupational exposure, sexual exposure, and other percutaneous infections.
¿The histologic diagnosis is not shown for one patient assigned to receive 90 µg of peginterferon
alfa-2a, because subsequent blinded review of the biopsy specimen obtained at base line showed that
the fibrosis score was less than 3.

response to 180 µg of peginterferon alfa-2a had had
a decrease in viral load by a factor of at least 100 as
compared with base line, and 23 of them had had
undetectable HCV RNA.
Peginterferon alfa-2a was also associated with a
higher rate of virologic response at the end of treatment (week 48) (Table 3). HCV RNA was undetectable at week 48 in 14 percent of the patients assigned
to receive interferon alfa-2a, as compared with 42 percent of the patients assigned to receive peginterferon
alfa-2a at a dose of 90 µg and 44 percent of the patients assigned to receive it at a dose of 180 µg
(P=0.001 for the comparison between each dose of

peginterferon alfa-2a and interferon alfa-2a). Although
the virologic rate of response at the end of treatment
was similar with the two doses of peginterferon alfa-2a,
the response was more likely to be sustained with the
180-µg dose.
Biochemical Response

A biochemical response was more likely to be sustained with the higher dose of peginterferon alfa-2a
(Table 3). The rates of biochemical response at week
72 were 15 percent, 20 percent, and 34 percent in
patients assigned to receive interferon alfa-2a, 90 µg
of peginterferon alfa-2a, and 180 µg of peginterferVol ume 343
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TABLE 2. RATES

OF DISCONTINUATION OF
AND DOSE MODIFICATION.*

INTERFERON
ALFA-2a
(N=88)

VARIABLE

on alfa-2a (P=0.004 for the comparison between
180 µg of peginterferon alfa-2a and interferon alfa-2a).
Normalization of alanine aminotransferase at week
48 occurred in significantly more of the patients assigned to peginterferon alfa-2a at either dose than of
those assigned to unmodified interferon (Table 3).
The percentages of patients who had both a biochemical and a virologic response at week 72 were
identical to the percentages who had a virologic response at that time (Table 3).

TREATMENT

PEGINTERFERON
ALFA-2a
90 µg
180 µg
(N=96)
(N=87)

number (percent)

Discontinuation of treatment
Due to adverse events
Due to laboratory abnormality
Due to insufficient therapeutic
response
Other reasons†
Dose modification‡
Due to neutropenia
Due to thrombocytopenia
Due to adverse event

7 (8)
2 (2)
5 (6)

7 (7)
4 (4)
2 (2)

11 (13)
1 (1)
1 (1)

10 (11)

5 (5)

7 (8)

12 (14)
5 (6)
12 (14)

9 (9)
17 (18)
2 (2)

9 (10)
16 (18)
12 (14)

Histologic Response

Most of the 271 patients enrolled had cirrhosis at
base line (Table 1). As is common with other trials in
patients with liver disease,2,3 nearly one third of the
patients did not return for second biopsies. Among the
184 patients with paired liver biopsies, the proportion who had a histologic response was lower among
the patients assigned to receive unmodified interferon (31 percent) than among those assigned to 90 µg
of peginterferon alfa-2a (44 percent [P=0.22]) and
those assigned to 180 µg (54 percent [P=0.02])

*Dose modification was defined as the reduction or omission of one or
more doses.
†Other reasons included administrative factors, refusal of treatment, failure to return for additional treatment, and protocol violation.
‡One or more doses were modified or were not given.

TABLE 3. VIROLOGIC, BIOCHEMICAL,

VARIABLE

INTERFERON
ALFA-2a
(N=88)

AND

HISTOLOGIC RESPONSES.*

PEGINTERFERON ALFA-2a

90 µg
(N=96)

180 µg
(N=87)

P VALUE
90 µg

180 µg

PEGINTERFERON

PEGINTERFERON

ALFA-2a VS.

ALFA-2a VS.

INTERFERON

INTERFERON

ALFA-2a

ALFA-2a

number (percent)

Virologic response
Week 48
12 (14)
40
Week 72
7 (8)
14
Biochemical response
Week 48
19 (22)
34
Week 72
13 (15)
19
Combined virologic and
biochemical response
Week 48
9 (10)
30
Week 72
7 (8)
14
Histologic response†
Week 72
17/55 (31) 27/61

(42)
(15)

38 (44)
26 (30)

0.001
0.27

0.001
0.001

(35)
(20)

34 (39)
30 (34)

0.03
0.47

0.02
0.004

(31)
(15)

25 (29)
26 (30)

0.001
0.27

0.004
0.001

0.22

0.02

(44) 37/68 (54)

*The assessments of efficacy were carried out by intention-to-treat analysis and included all enrolled patients, regardless of whether they withdrew from the study prematurely or discontinued
treatment. A virologic response was defined as an undetectable level of HCV RNA (<100 copies per
milliliter). A biochemical response was defined as an alanine aminotransferase value below the upper
limit of normal. A histologic response was defined as a decrease of at least 2 points in the total score
on the Histological Activity Index (on which a score of 3 indicates bridging fibrosis, and a score of
4 cirrhosis).
†Values are the numbers of patients with a histologic response divided by the total number with
paired biopsy specimens.
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(Table 3). A histologic response correlated with a sustained virologic response; among the patients with a
virologic response at week 72, 80 percent of those
assigned to receive interferon alfa-2a also had a histologic response, as did 100 percent of those assigned
to 90 µg of peginterferon alfa-2a and 88 percent of
those assigned to the 180-µg dose. The virologic response was similar among patients with bridging fibrosis or cirrhosis. A histologic response was seen in 26
percent, 33 percent, and 35 percent, respectively, of
patients who did not have a sustained virologic response. The histologic response also correlated with

TABLE 4. RATES

OF

the biochemical response at week 72: 40 percent, 79
percent, and 82 percent of the patients who had a biochemical response to interferon alfa-2a or peginterferon alfa-2a at 90 µg or 180 µg, respectively, also had
a histologic response.
Correlation of Base-Line Characteristics with Virologic
Response

The rates of sustained virologic response with respect to pretreatment variables are presented in Table
4. Treatment with peginterferon alfa-2a was consistently associated with higher rates of sustained viro-

VIROLOGIC RESPONSE AT WEEK 72 AS
PROGNOSTIC VARIABLES.*

VARIABLE

INTERFERON
ALFA-2a
(N=88)†

A

FUNCTION

OF

BASE-LINE

PEGINTERFERON ALFA-2a
90 µg
(N=96)

180 µg
(N=87)

no. with response/total no. (%)

Alanine aminotransferase quotient‡
«3
>3
HCV RNA level (copies/ml)
«2,000,000
>2,000,000
HCV genotype
1
1a
1b
Other than 1 or unknown
Total Histological Activity Index score¶
«10
>10
Histologic diagnosis¿
Cirrhosis
Bridging fibrosis
HCV genotype in relation to RNA level
1
«2,000,000
>2,000,000
Other than 1
«2,000,000
>2,000,000
Unknown
«2,000,000
>2,000,000

2/48 (4)
5/40 (12)

8/52 (15)
6/44 (14)

7/28 (25)
19/59 (32)

2/41 (5)
4/45 (9)

10/45 (22)
4/51 (8)

16/43 (37)
10/44 (23)

1/47 (2)
0/28
1/19 (5)§
6/41 (15)

3/58
1/27
2/31
11/38

6/48
3/33
3/15
20/39

0/5
7/83 (8)

1/13 (8)
13/83 (16)

2/5 (40)
24/82 (29)

5/67 (7)
2/21 (10)

11/76 (14)
3/19 (16)

22/69 (32)
4/18 (22)

0/21
1/25 (4)§

3/26 (12)
0/32

3/19 (16)
3/29 (10)

2/20 (10)
4/20 (20)

6/18 (33)
4/18 (22)

12/22 (55)
7/14 (50)

—
—

(5)
(4)
(6)
(29)

1/1 (100)
0/1

(12)
(9)
(20)
(51)

1/2 (50)
0/1

*Values are the numbers of patients with a virologic response at week 72 divided by the numbers
with the given base-line variable. A virologic response was defined as an undetectable level of HCV
RNA (<100 copies per milliliter).
†HCV RNA levels were not measured in the two patients in this group who did not receive treatment.
‡The alanine aminotransferase quotient is the average of the alanine aminotransferase values before
treatment divided by the upper limit of normal.
§This patient elected to continue treatment with an alternative regimen of interferon alfa-2a at the
end of follow-up and was receiving interferon alfa-2a at the time of the assessment at week 72.
¶The total Histological Activity Index score is the sum of two scores, one for inflammation
(0 [none] to 18 [severe]) and one for fibrosis (0 [none] to 4 [cirrhosis]); a fibrosis score of 3 indicates
bridging fibrosis.
¿The histologic diagnosis is not shown for one patient assigned to receive 90 µg of peginterferon
alfa-2a, because subsequent blinded review of the biopsy specimen obtained at base line showed that
the fibrosis score was less than 3.
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logic response among subgroups of patients defined
by factors such as genotype and pretreatment viral
load. Among patients with cirrhosis, the rate of sustained virologic response associated with the dose of
180 µg of peginterferon alfa-2a was more than four
times that associated with the dose of interferon alfa2a (32 percent vs. 7 percent). Among patients infected with HCV genotype 1, the rates of sustained virologic response were 2 percent, 5 percent, and 13
percent, respectively, in those assigned to interferon
alfa-2a and peginterferon alfa-2a at 90 µg and 180
µg. Treatment with 180 µg of peginterferon alfa-2a
was more efficacious in treating infection with genotype 1b than infection with genotype 1a (rates of
virologic response at week 72, 20 percent and 9 percent). Among patients with HCV genotypes other
than 1 (or with no data on genotype), the rates of
sustained virologic response were 15 percent, 29 percent, and 51 percent, respectively, in patients assigned
to interferon and peginterferon alfa-2a at 90 µg and
180 µg. Among patients with a combination of poor
prognostic factors (infection with genotype 1 and a
high viral load at base line [>2,000,000 copies per
milliliter]), 10 percent of those assigned to 180 µg
of peginterferon alfa-2a and none of those assigned
to 90 µg had a sustained virologic response.
Safety

Information about discontinuation of treatment
and dose modifications is shown in Table 2. In patients with cirrhosis, exacerbation of cirrhosis-related neutropenia and thrombocytopenia is a risk associated with the use of interferon. In this study, the
mean (±SD) neutrophil counts at base line were
3400±2100, 3400±1200, and 3100±1100 per cubic
millimeter, respectively, in patients assigned to receive
unmodified interferon alfa-2a, 90 µg of peginterferon alfa-2a, and 180 µg of peginterferon alfa-2a. These
values decreased shortly after the initiation of treatment but stabilized during treatment and then rapidly returned to base-line values after the end of treatment. The proportion of patients with a neutrophil
count below 500 per cubic millimeter at any time during treatment was similar in the three groups (3 percent with interferon alfa-2a, and 3 percent and 1 percent with 90 µg and 180 µg of peginterferon alfa-2a,
respectively). In none of the patients did a serious
infection or sepsis associated with neutropenia develop. Dose modification (defined as reduction or
omission of one or more doses of study medication)
because of neutropenia was deemed necessary in 14
percent of the patients assigned to interferon alfa-2a
and 9 percent and 11 percent of those assigned to 90
µg and 180 µg of peginterferon alfa-2a, respectively.
Only rarely (in two patients receiving peginterferon
alfa-2a at 180 µg) was permanent dose modification
necessary, and no patient discontinued treatment because of neutropenia.
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In most of the patients the total platelet count decreased to some extent during treatment. At base line,
the mean platelet counts were 153,000±51,300,
162,000±54,100, and 166,000±50,600 per cubic
millimeter in the patients assigned to interferon alfa2a, 90 µg of peginterferon alfa-2a, and 180 µg of
peginterferon alfa-2a. These values reached a nadir of
128,000±47,600, 110,000±42,300, and 108,000±
50,100 per cubic millimeter, respectively, by week 8.
The platelet count decreased to a level below the entry criterion of 75,000 per cubic millimeter in 27 percent, 48 percent, and 46 percent of patients, respectively. The proportion of patients with a platelet count
below 50,000 per cubic millimeter at any time during treatment was significantly lower among those assigned to interferon alfa-2a (7 percent) than among
those assigned to peginterferon alfa-2a at 90 µg (26
percent, P<0.001) or 180 µg (19 percent, P=0.04).
None of the patients had clinically significant bleeding associated with thrombocytopenia. Dose modification was deemed necessary because of thrombocytopenia in 6 percent, 18 percent, and 19 percent
of the patients receiving interferon and 90 µg and
180 µg of peginterferon alfa-2a, respectively; permanent dose modification was necessary in 4 percent,
8 percent, and 13 percent. Discontinuation of therapy because of thrombocytopenia was infrequent (it
was required in 2 percent, 4 percent, and 2 percent
of patients, respectively).
In all three treatment groups, the adverse events
were typical of those produced by unmodified interferon alfa. Table 5 summarizes the adverse events that
were reported during treatment or within eight weeks
after the end of treatment. The incidence of most of
the adverse events was similar in the three treatment
groups; the most commonly reported events were fatigue, headache, myalgia, rigors, and pyrexia. A higher
proportion of the patients assigned to receive peginterferon alfa-2a at a dose of 180 µg had myalgia and inflammation at the injection site than of patients in the
other two groups. Dose modification was necessary
because of adverse events in 14 percent of the patients assigned to interferon alfa-2a and in 2 percent
and 14 percent of those assigned to peginterferon
alfa-2a at 90 µg and 180 µg, respectively. Treatment
was discontinued because of adverse events in 8 percent, 7 percent, and 13 percent of patients, respectively (Table 2).
Four deaths were reported, one in a patient assigned
to receive 90 µg of peginterferon alfa-2a and three
in patients assigned to receive 180 µg. Two patients
died of hepatic failure, 420 and 179 days after the end
of treatment; one patient died of hepatic neoplasm,
219 days after the end of treatment; and one patient
who had received 180 µg of peginterferon alfa-2a died
of a cerebral hemorrhage after a suspected methadone
overdose, 24 days after the end of treatment. In the
latter patient, the platelet count was 64,000 per cu-
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TABLE 5. INCIDENCE

OF ADVERSE
OR WITHIN THE FIRST EIGHT

EVENTS DURING TREATMENT
WEEKS OF FOLLOW-UP.*

INTERFERON
ALFA-2a
(N=86)

ADVERSE EVENT

PEGINTERFERON
ALFA-2a
90 µg
(N=96)

180 µg
(N=86)

number (percent)

Fatigue
Headache
Myalgia
Rigors
Pyrexia
Nausea
Upper abdominal pain
Depression
Diarrhea
Inflammation at injection site
Insomnia
Alopecia
Dizziness
Pruritus
Vomiting
Decreased appetite
Cough
Dermatitis
Epistaxis
Pain
Sinusitis
Impaired concentration
Pain in limb
Anxiety

52 (60)
46 (53)
33 (38)
39 (45)
31 (36)
29 (34)
21 (24)
18 (21)
16 (19)
12 (14)
19 (22)
19 (22)
14 (16)
7 (8)
13 (15)
6 (7)
4 (5)
6 (7)
12 (14)
10 (12)
6 (7)
10 (12)
4 (5)
6 (7)

51 (53)
52 (54)
35 (36)
36 (38)
28 (29)
29 (30)
18 (19)
20 (21)
20 (21)
14 (15)
18 (19)
14 (15)
19 (20)
15 (16)
12 (12)
14 (15)
10 (10)
8 (8)
11 (11)
10 (10)
12 (12)
6 (6)
11 (11)
11 (11)

53 (62)
43 (50)
44 (51)
37 (43)
33 (38)
29 (34)
22 (26)
22 (26)
21 (24)
27 (31)
16 (19)
15 (17)
13 (15)
14 (16)
11 (13)
12 (14)
15 (17)
15 (17)
6 (7)
9 (10)
7 (8)
6 (7)
7 (8)
3 (3)

*The adverse events listed are those that occurred in at least 10 percent
of the patients. Values are based on the patients who received at least one
dose of study medication.

bic millimeter on admission; subsequently, sepsis complicated by a coagulopathy developed, with a platelet
count of 15,000 per cubic millimeter the day before
death.
DISCUSSION

Patients with chronic HCV infection and advanced
liver disease usually have poor responses to treatment
with interferons.7,8,17,18 Our study found that peginterferon alfa-2a produces higher rates of virologic,
biochemical, and histologic responses than unmodified interferon alfa-2a among patients with chronic
HCV infection and related compensated cirrhosis or
bridging fibrosis. In most patients who had a virologic response at week 72, this sustained response
could be predicted by measurement of HCV RNA
at week 12. Our results are similar to those obtained
in a large trial involving patients with chronic HCV
infection who were treated with the same formula-

tion of modified interferon alfa-2a and who did not
necessarily have cirrhosis.12
When plasma HCV RNA is undetectable, hepatic
inflammation is diminished, and further progression
of liver disease may be prevented. In the current trial, more than half the patients assigned to receive
180 µg of peginterferon alfa-2a who had paired biopsy specimens had a histologic response at week
72, regardless of the virologic or biochemical response.
Even among patients who did not have a virologic
response, more than a third had histologic improvement, suggesting that patients who do not have a virologic response may still benefit from treatment with
peginterferon alfa-2a. This finding confirms a previous report of histologic benefit in patients who were
treated with unmodified interferon and who did not
have a virologic response.19
At week 48, the percentage of patients assigned to
either dose of peginterferon alfa-2a who did not have
a virologic response was higher than the percentage
of patients in these two groups who had a biochemical response. This discordance resolved after the end
of treatment and did not appear to affect the rates of
histologic response. The reason for this discordance
is unknown. This finding further supports the use of
recently developed tests for HCV RNA, rather than
measurement of alanine aminotransferase, for monitoring the efficacy of therapy in patients with chronic
HCV infection.
Use of interferon in the treatment of patients with
cirrhosis has been limited by observations that patients
may frequently have associated adverse effects, particularly toxic effects on bone marrow. The patients in
our study often had substantial decreases in neutrophil and platelet counts during treatment, and some
of the patients in each of the three treatment groups
required dose modifications. Treatment was not discontinued in any patient because of neutropenia, and
thrombocytopenia necessitated discontinuation of
treatment in only two of the patients assigned to the
180-µg dose of peginterferon alfa-2a. None of the patients had a systemic infection, serious hemorrhage,
or hepatic decompensation. In general, the adverse
events in patients assigned to peginterferon alfa-2a at
either dose were typical of those seen with standard
interferon. Treatment was discontinued because of adverse events in 8 percent of the patients assigned to
interferon alfa-2a and in 7 percent and 13 percent of
those assigned to peginterferon alfa-2a at 90 µg and
180 µg, respectively.
The use of a combination of peginterferon alfa-2a
and ribavirin will require evaluation by direct comparison with a combination of standard interferon
and ribavirin. Although a phase 2 study of peginterferon alfa-2a and ribavirin has been conducted, full
results are not yet available.20
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